For decades, medical treatment has often followed a familiar formula: diagnose the disease and prescribe the treatment that has worked for most patients.

Genomics is beginning to challenge that approach.

Scientists are discovering that differences in people’s genes can influence their susceptibility to certain diseases and, in some cases, their response to specific medicines.

This has helped drive the development of precision medicine, which uses information about an individual patient, including genetic data, to guide prevention, diagnosis, and treatment.

The idea is straightforward: instead of asking only what disease a patient has, doctors may increasingly ask what makes that patient’s disease biologically distinct.

Genomics has become particularly important in cancer research.

Cancer is not a single disease. Tumours can harbour different genetic changes, and identifying them can help doctors understand how a cancer behaves and which treatments may be appropriate.

Genomic testing is also helping researchers investigate rare inherited conditions. For families who have spent years searching for an explanation for an unexplained illness, identifying a genetic cause can provide answers that conventional testing may not have uncovered.

However, the growth of genomic medicine also poses challenges.

Genetic tests can be expensive, and access to specialist services remains uneven across countries. Without careful planning, precision medicine could become a privilege available mainly to those in wealthier healthcare systems.

Genetic counselling is another issue.

A genetic result can affect not only a patient but also their relatives. Patients need qualified professionals who can explain what a result means and what it does not mean.

For Africa and other developing regions, expanding genomic medicine will require investment in laboratories, trained professionals, research, and data infrastructure.

The promise of genomics is profound.

It could help medicine move away from a one-size-fits-all approach towards treatment increasingly informed by each individual's biology.

But the success of that revolution will ultimately depend on ensuring that precision does not come at the expense of access and equity.